<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">transmed</journal-id><journal-title-group><journal-title xml:lang="ru">Трансляционная медицина</journal-title><trans-title-group xml:lang="en"><trans-title>Translational Medicine</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2311-4495</issn><issn pub-type="epub">2410-5155</issn><publisher><publisher-name>Almazov National Medical Research Centre, Saint Petersburg, Russia</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.18705/2311-4495-2023-10-2-116-122</article-id><article-id custom-type="elpub" pub-id-type="custom">transmed-813</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>СЕРДЕЧНО-СОСУДИСТЫЕ ЗАБОЛЕВАНИЯ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>CARDIOVASCULAR MEDICINE</subject></subj-group></article-categories><title-group><article-title>Прогноз у пациентов с кардиоренальным синдромом в зависимости от клинической формы фибрилляции предсердий</article-title><trans-title-group xml:lang="en"><trans-title>Prognosis in patients with cardiorenal syndrome depending on the clinical form of atrial fibrillation</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-3694-3647</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Полянская</surname><given-names>Е. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Polyanskaya</surname><given-names>E. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Полянская Елена Александровна, к.м.н., доцент кафедры пропедевтики внутренних болезней № 2</p><p>ул. Петропавловская, д. 26, Пермь, 614000</p></bio><bio xml:lang="en"><p>Elena A. Polyanskaya, Phd, associate professor, Department of propaedeutics of internal diseases № 2</p><p>Petropavlovskaya str., 26, Perm, 61400</p></bio><email xlink:type="simple">eapolyanskaya@gmail.com</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Федеральное государственное бюджетное образовательное учреждение высшего образования «Пермский государственный медицинский университет имени академика Е. А. Вагнера» Министерства здравоохранения Российской Федерации</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Academician E. A. Wagner Perm State Medical University</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2023</year></pub-date><pub-date pub-type="epub"><day>20</day><month>05</month><year>2023</year></pub-date><volume>10</volume><issue>2</issue><fpage>116</fpage><lpage>122</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Полянская Е.А., 2023</copyright-statement><copyright-year>2023</copyright-year><copyright-holder xml:lang="ru">Полянская Е.А.</copyright-holder><copyright-holder xml:lang="en">Polyanskaya E.A.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://transmed.almazovcentre.ru/jour/article/view/813">https://transmed.almazovcentre.ru/jour/article/view/813</self-uri><abstract><sec><title>Актуальность</title><p>Актуальность. Фибрилляция предсердий (ФП) является наиболее широко распространенной в популяции стабильной аритмией. Взаимодействие ФП и кардиоренального синдрома малоизучено, несмотря на то, что доля таких больных с сочетанным поражением сердца и почек достигает 60 % среди лиц с хронической сердечной недостаточностью (ХСН). Данных о долгосрочном прогнозе у пациентов с кардиоренальным синдромом в зависимости от формы ФП недостаточно.</p></sec><sec><title>Цель</title><p>Цель. Оценить прогноз у пациентов с кардиоренальным синдромом в зависимости от клинической формы ФП.</p></sec><sec><title>Материалы и методы</title><p>Материалы и методы. Включены 126 пациентов с верифицированным кардиоренальным синдромом и различными формами ФП. Произведено наблюдательное исследование с фиксацией госпитализаций по поводу ХСН и других сердечно-сосудистых событий, включая летальные исходы.</p></sec><sec><title>Результаты</title><p>Результаты. Скорость наступления первой конечной точки выше у пациентов с перманентной формой ФП (8,5 [3,0; 18,5] месяца и 15,0 [5,0; 24,0] месяцев, р &lt; 0,001). Анализ кривых выживаемости демонстрирует худший прогноз у больных с перманентной формой ФП.</p></sec><sec><title>Заключение</title><p>Заключение. У пациентов с кардиоренальным синдромом в сочетании с ФП ее клиническая форма оказывает существенное влияние на долгосрочный прогноз. Перманентная форма ФП в большей степени, чем пароксизмальная/персистирующая ФП, в условиях кардиоренального синдрома ассоциируется с более быстрым и частым развитием новых сердечно-сосудистых событий, включая госпитализации по поводу декомпенсации ХСН и летальные исходы.</p></sec></abstract><trans-abstract xml:lang="en"><sec><title>Background</title><p>Background. Atrial fibrillation (AF) is the most common stable arrhythmia in the population. The interaction of AF and cardiorenal syndrome is poorly understood, despite the fact that the proportion of such patients with combined heart and kidney damage reaches 60% among people with chronic heart failure (CHF). Data on the long-term prognosis in patients with cardiorenal syndrome depending on the form of AF is not enough.</p></sec><sec><title>Objective</title><p>Objective. To assess the prognosis in patients with cardiorenal syndrome depending on the clinical form of AF.</p></sec><sec><title>Design and methods</title><p>Design and methods. 126 patients with verified cardiorenal syndrome and various forms of AF were included. An observational study was performed with the fixation of hospitalizations for CHF and other cardiovascular events, including deaths.</p></sec><sec><title>Results</title><p>Results. The rate of onset of the first end point is higher in patients with permanent AF (8.5 [3.0; 18.5] months and 15.0 [5.0; 24.0] months, p &lt; 0.001). Analysis of survival curves shows a worse prognosis in patients with permanent AF.</p></sec><sec><title>Conclusion</title><p>Conclusion. In patients with cardiorenal syndrome in combination with AF, its clinical form has a significant impact on the long-term prognosis. Permanent AF, to a greater extent than paroxysmal/persistent AF, in conditions of cardiorenal syndrome is associated with faster and more frequent development of new cardiovascular events, including hospitalizations for decompensated CHF and deaths.</p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>госпитализация</kwd><kwd>кардиоренальный синдром</kwd><kwd>летальный исход</kwd><kwd>неблагоприятный прогноз</kwd><kwd>перманентная форма фибрилляции предсердий</kwd><kwd>персистирующая форма фибрилляции предсердий</kwd></kwd-group><kwd-group xml:lang="en"><kwd>cardiorenal syndrome</kwd><kwd>hospitalization</kwd><kwd>lethal outcome</kwd><kwd>permanent atrial fibrillation</kwd><kwd>persistent atrial fibrillation</kwd><kwd>unfavorable prognosis</kwd></kwd-group><funding-group><funding-statement xml:lang="ru">исследование проведено без использования спонсорской поддержки</funding-statement></funding-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Benjamin EJ, Muntner P, Alonso A, et al. Heart Disease and Stroke Statistics-2019 Update: A Report From the American Heart Association. Circulation. 2019; 139(10):e56–e528. DOI: 10.1161/CIR.0000000000000659.</mixed-citation><mixed-citation xml:lang="en">Benjamin EJ, Muntner P, Alonso A, et al. Heart Disease and Stroke Statistics-2019 Update: A Report From the American Heart Association. Circulation. 2019; 139(10):e56–e528. DOI: 10.1161/CIR.0000000000000659.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Zafrir B, Lund LH, Laroche C, et al. Prognostic implications of atrial fibrillation in heart failure with reduced, mid-range, and preserved ejection fraction: a report from 14 964 patients in the European Society of Cardiology Heart Failure Long-Term Registry. Eur Heart J. 2018; 39(48):4277–4284. DOI: 10.1093/eurheartj/ehy626.</mixed-citation><mixed-citation xml:lang="en">Zafrir B, Lund LH, Laroche C, et al. Prognostic implications of atrial fibrillation in heart failure with reduced, mid-range, and preserved ejection fraction: a report from 14 964 patients in the European Society of Cardiology Heart Failure Long-Term Registry. Eur Heart J. 2018; 39(48):4277–4284. DOI: 10.1093/eurheartj/ehy626.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Bansal N, Xie D, Tao K, et al. Atrial Fibrillation and Risk of ESRD in Adults with CKD. Clin J Am Soc Nephrol. 2016; 11(7):1189–1196. DOI: 10.2215/CJN.10921015.</mixed-citation><mixed-citation xml:lang="en">Bansal N, Xie D, Tao K, et al. Atrial Fibrillation and Risk of ESRD in Adults with CKD. Clin J Am Soc Nephrol. 2016; 11(7):1189–1196. DOI: 10.2215/CJN.10921015.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Chen TH, Chu YC, Ou SM, et al. Associations of atrial fibrillation with renal function decline in patients with chronic kidney disease. Heart. 2022; 108(6):438–444. DOI: 10.1136/heartjnl-2021-319297.</mixed-citation><mixed-citation xml:lang="en">Chen TH, Chu YC, Ou SM, et al. Associations of atrial fibrillation with renal function decline in patients with chronic kidney disease. Heart. 2022; 108(6):438–444. DOI: 10.1136/heartjnl-2021-319297.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Rangaswami J, Bhalla V, Blair JEA, et al. Cardiorenal Syndrome: Classification, Pathophysiology, Diagnosis, and Treatment Strategies: A Scientific Statement From the American Heart Association. Circulation. 2019; 139(16):e840–e878. DOI: 10.1161/CIR.0000000000000664.</mixed-citation><mixed-citation xml:lang="en">Rangaswami J, Bhalla V, Blair JEA, et al. Cardiorenal Syndrome: Classification, Pathophysiology, Diagnosis, and Treatment Strategies: A Scientific Statement From the American Heart Association. Circulation. 2019; 139(16):e840–e878. DOI: 10.1161/CIR.0000000000000664.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Мухин Н.А., Глыбочко П.В., Свистунов А.А. и др. Хроническая болезнь почек и фибрилляция предсердий как компоненты кардиоренального континуума. Терапевтический архив. 2016; 88(6):4–8]. DOI: 10.17116/terarkh20168864-8.</mixed-citation><mixed-citation xml:lang="en">Mukhin NA, Glybochko PV, Svistunov AA, et al. Chronic kidney disease and atrial fibrillation as components of the cardiorenal continuum. Terapevticheskii Arkhiv. 2016; 88(6):4–8. In Russian DOI: 10.17116/terarkh20168864-8.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Hanna-Rivero N, Tu SJ, Elliott AD, et al. Anemia and iron deficiency in patients with atrial fibrillation. BMC Cardiovasc Disord. 2022; 22(1):204. DOI: 10.1186/s12872022-02633-6.</mixed-citation><mixed-citation xml:lang="en">Hanna-Rivero N, Tu SJ, Elliott AD, et al. Anemia and iron deficiency in patients with atrial fibrillation. BMC Cardiovasc Disord. 2022; 22(1):204. DOI: 10.1186/s12872022-02633-6.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Alnuwaysir RIS, Grote Beverborg N, Hoes MF, et al. Additional burden of iron deficiency in heart failure patients beyond the cardio-renal anaemia syndrome: findings from the BIOSTAT-CHF study. Eur J Heart Fail. 2022; 24(1):192–204. DOI: 10.1002/ejhf.2393.</mixed-citation><mixed-citation xml:lang="en">Alnuwaysir RIS, Grote Beverborg N, Hoes MF, et al. Additional burden of iron deficiency in heart failure patients beyond the cardio-renal anaemia syndrome: findings from the BIOSTAT-CHF study. Eur J Heart Fail. 2022; 24(1):192–204. DOI: 10.1002/ejhf.2393.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Hao C, Luo J, Liu B, et al. Prognostic Significance of New-Onset Atrial Fibrillation in Heart Failure with Preserved, Mid-Range, and Reduced Ejection Fraction Following Acute Myocardial Infarction: Data from the NOAFCAMI-SH Registry. Clin Interv Aging. 2022; 17:479–493. DOI: 10.2147/CIA.S358349.</mixed-citation><mixed-citation xml:lang="en">Hao C, Luo J, Liu B, et al. Prognostic Significance of New-Onset Atrial Fibrillation in Heart Failure with Preserved, Mid-Range, and Reduced Ejection Fraction Following Acute Myocardial Infarction: Data from the NOAFCAMI-SH Registry. Clin Interv Aging. 2022; 17:479–493. DOI: 10.2147/CIA.S358349.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Kolben Y, Kessler A, Puris G, et al. Management of heart failure with reduced ejection fraction: challenges in patients with atrial fibrillation, renal disease and in the elderly. Rev Cardiovasc Med. 2022; 23(1):16. DOI: 10.31083/j.rcm2301016.</mixed-citation><mixed-citation xml:lang="en">Kolben Y, Kessler A, Puris G, et al. Management of heart failure with reduced ejection fraction: challenges in patients with atrial fibrillation, renal disease and in the elderly. Rev Cardiovasc Med. 2022; 23(1):16. DOI: 10.31083/j.rcm2301016.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Жиров И.В., Сафронова Н.В., Осмоловская Ю.Ф. и др. Прогностическое значение фибрилляции предсердий у пациентов с сердечной недостаточностью с разной фракцией выброса левого желудочка: результаты многоцентрового регистра РИФ-ХСН. Российский кардиологический журнал. 2021; 26(1):4200]. DOI: 10.15829/1560-40712021-4200.</mixed-citation><mixed-citation xml:lang="en">Zhirov IV, Safronova NV, Osmolovskaya YuF, et al. Prognostic value of atrial fibrillation in patients with heart failure and different left ventricular ejection fraction: results of the multicenter RIF-CHF register. Russian Journal of Cardiology. 2021; 26(1):4200. In Russian DOI: 10.15829/1560-40712021-4200.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Sartipy U, Dahlström U, Fu M, et al. Atrial Fibrillation in Heart Failure With Preserved, Mid-Range, and Reduced Ejection Fraction. JACC Heart Fail. 2017; 5(8):565–574. DOI: 10.1016/j.jchf.2017.05.001.</mixed-citation><mixed-citation xml:lang="en">Sartipy U, Dahlström U, Fu M, et al. Atrial Fibrillation in Heart Failure With Preserved, Mid-Range, and Reduced Ejection Fraction. JACC Heart Fail. 2017; 5(8):565–574. DOI: 10.1016/j.jchf.2017.05.001.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Ардашев А.В., Беленков Ю.Н., Матюкевич М.Ч. и др. Фибрилляция предсердий и смертность: прогностические факторы и терапевтические стратегии. Кардиология. 2021; 61(2):91–98]. DOI: 10.18087/cardio.2021.2.n1348.</mixed-citation><mixed-citation xml:lang="en">Ardashev AV, Belenkov YuN, Matsiukevich MC, et al. Atrial Fibrillation and Mortality: Prognostic Factors and Direction of Prevention. Kardiologiia. 2021; 61(2):91– 98. In Russian DOI: 10.18087/cardio.2021.2.n1348.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Heijman J, Luermans JGLM, Linz D, et al. Risk Factors for Atrial Fibrillation Progression. Card Electrophysiol Clin. 2021;13(1):201–209. DOI: 10.1016/j.ccep.2020.10.011.</mixed-citation><mixed-citation xml:lang="en">Heijman J, Luermans JGLM, Linz D, et al. Risk Factors for Atrial Fibrillation Progression. Card Electrophysiol Clin. 2021;13(1):201–209. DOI: 10.1016/j.ccep.2020.10.011.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
